The FDA re­fus­es to lift a clin­i­cal hold on Cel-Sci’s PhI­II drug

Pen­ny stock biotech, Cel-Sci, re­mains in the FDA’s dog house.

Last fall, the biotech re­port­ed that the FDA had put their Phase III study for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.